#United States #San Diego #Aethlon Medical #Hemopurifier #Oncology Trials

Aethlon Medical's Q3 2026 Overview

Aethlon Medical, Inc. (NASDAQ: AEMD), a pioneering medical therapeutic firm located in San Diego, California, has shared its financial results for the fiscal third quarter ending on December 31, 2025. The company, which focuses on developing products for cancer treatment and life-threatening infectious diseases, continues to make strides in its clinical and research programs, while also achieving significant cost efficiencies.

Financial Highlights

• - Cash on Hand: As of December 31, 2025, Aethlon reported available cash of approximately $7.0 million.
• - Operating Expenses: The company's operating expenses totaled around $2.06 million for the quarter, reflecting a 13.6% increase compared to $1.81 million for the same period in 2024. The rise in costs was primarily due to payroll increases, despite the firm achieving a critical reduction in administrative expenses.
• - Overall Loss: Consequently, the operating loss for the quarter increased to $2.06 million, compared to $1.81 million for the previous year.

Clinical Advancements

Aethlon Medical is actively progressing in its clinical trial program, particularly in its Australian oncology trial that includes Cohort 2. This phase tests the safety and feasibility of Hemopurifier treatments on patients with solid tumors who have stable or progressing diseases being treated with anti-PD-1 agents, such as Keytruda and Opdivo.

• - The promising results from Cohort 1 showed improvements in immune cell numbers alongside solid safety and tolerability.
• - The ongoing technology development includes a Material Transfer Agreement (MTA) with Stavro to assess the Hemopurifier's compatibility with their SLAMB system—a simplified blood treatment platform that could allow its use in infusion centers without extensive dialysis setups.

Scientific Developments

In terms of scientific progress, Aethlon's research and development team is making strides in studying extracellular vesicles (EVs), particularly in relation to Long COVID. Recent findings demonstrated that the GNA affinity resin effectively binds to EVs from Long COVID patients, indicating a significant reduction in microRNAs associated with immune dysregulation. These findings are crucial as they have been published on bioRxiv for further peer review.

• - Aethlon continues to explore the potential for the Hemopurifier not only as a cancer treatment device but also for its applications in various diseases linked with EVs, including autoimmune disorders like Lupus and Multiple Sclerosis.

Operational Efficiency

The company has managed to reduce its nine-month operating expenses to approximately $5.36 million compared to the $7.34 million reported for the previous year. This substantial decrease in spending reflects Aethlon's ongoing commitment to operational efficiency while simultaneously advancing its innovation in clinical and research programs.

CEO's Remarks

James Frakes, CEO and CFO of Aethlon Medical, emphasized, "We remain committed to advancing our clinical programs and research initiatives with operational discipline. Recent progress in our trials, research collaborations, and technology development continues to move us closer to delivering therapeutic solutions for cancer and life-threatening infectious diseases."

Upcoming Conference Call

On February 12, 2026, management will hold a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate updates. Interested parties can register through the provided link or dial in to participate directly. A replay will be available following the call for those unable to attend live.

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational device designed to extract enveloped viruses and tumor-derived extracellular vesicles from the bloodstream. The device works extracorporeally using plasma separation and affinity binding with a plant lectin resin that targets unique virus and EV surfaces. The Hemopurifier has received Breakthrough Device Designation from the U.S. FDA for treating advanced or metastatic cancer and life-threatening viruses.

Conclusion

Aethlon Medical is making significant progress in both financial and clinical aspects. The advancements in their oncology trials and continued exploration of new therapeutic applications position the company as a key player in the medical field, particularly in cancer research and infectious diseases.

For more information, visit www.AethlonMedical.com.